PIDOTIMOD ACTIVITY AGAINST CHRONIC-BRONCHITIS EXACERBATIONS

The efficacy of pidotimod 2-pyrrolidinyl)carbonyl]-thiazolidine-4-carb oxylic acid, PGT/1A, CAS 121808-62-6) in the management of infectious exacerbations of chronic bronchitis was evaluated in a double-blind, p lacebo-controlled study in parallel groups over 5 months (60 days of t reatment and 90 days of follow-up). The study enrolled 580 patients, o f whom 514 could be evaluated. The pidotimod group had fewer and short er infectious episodes, fewer days of antibiotic therapy and fewer day s unable to undertake normal activities. The difference vs. placebo wa s significant during the follow-up period and, in those subjects with a less severe history, during the treatment period also. Pidotimod was well tolerated.